Security key
88338N206
TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD)
CUSIP: 88338N206
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 3,666,322
- Total 13F value
- $8,101,690
- Share change
- -255,039
- SEC-reported price per share
- $2.21
- Number of holders
- 44
- Value change
- -$480,563
- Number of buys
- 16
- Number of sells
- 10
- Shares outstanding
- 11,627,985
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
44
Top holders
10
TXMD full security history
Ownership snapshot
Full 13F holder table
TherapeuticsMD, Inc. SEC filings
TherapeuticsMD, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Baselake Partners, LP
Disclosed value leader
Rubric Capital Management LP
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 6.8%
13D/G row: Baselake Partners, LP
Showing 1-6 of 15 holder rows.
Quick read
Baselake Partners, LP leads the comparable SEC ownership view at 6.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Baselake Partners, LP's linked filing trail.
Comparable ownership
Top 5
Baselake Partners, LP
6.8%
Clearline Capital LP
5.5%
Rubric Capital Management LP
10%
Squadron Capital Management LLC
3.6%
VANGUARD CAPITAL MANAGEMENT LLC
3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Baselake Partners, LP |
13D/G
|
6.8%
|
$1,668,383
790,703 shares
|
+$387,231 | 30 Jun 2026 |
| Clearline Capital LP |
13F
13D/G
Company
|
5.5%
from 13D/G
|
$1,283,148
635,222 shares
|
— | 31 Mar 2026 |
| Rubric Capital Management LP |
3/4/5
13F
Director, Other*, 10%+ Owner · Company
|
10%
from 13F
|
$6,718,950
2,946,908 shares
|
— | 15 Nov 2023 |
| Squadron Capital Management LLC |
13F
Company
|
3.6%
|
$849,250
420,421 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3%
|
$714,468
353,697 shares
|
— | 31 Mar 2026 |
| Tejara Capital Ltd |
13F
Company
|
3%
|
$698,621
345,852 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
44
Shares
3,666,322
Rows available
44
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
47
Q2 2026 holders
44
Holder diff
-3
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|